Experimental vaccines in animal models for schistosomiasis.
Considerable morbidity and mortality results from the affliction of an estimated 200 million people worldwide by several species of schistosomes; 779 million are exposed to the disease in 74 different countries. Even though anti-parasitic drugs and other control measures, including public hygiene and snail control are available, the advent of an effective vaccine still remains the most potentially powerful means for the control of this disease. The putative vaccine could be administered to small children prior to the time when their contact with infected water is maximal, so as to prevent severe infection in the subsequent years. This review attempts to summarize the status of schistosome vaccine development with special emphasis on functionally important vaccine candidates. The importance of utilizing both murine and nonhuman primate models as a prerequisite for clinical trials is discussed.
Siddiqui
Afzal A
AA
Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, Stop 6591, Lubbock, TX 79430-6591, USA. Afzal.Siddiqui@ttuhsc.edu
Ahmad
Gul
G
Damian
Raymond T
RT
Kennedy
Ronald C
RC
D000818:Animals; D000947:Antigens, Helminth / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D010215:Papio; D012552:Schistosomiasis / Q000469:parasitology / Q000517:prevention & control*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology
D000947:Antigens, Helminth; D014612:Vaccines